EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)VergleichsstudieMultizentrische StudieRandomisierte kontrollierte Studie

Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer

Thomas Powles, Begoña P Valderrama, Shilpa Gupta, Jens Bedke, Eiji Kikuchi, Jean Hoffman-Censits, Gopa Iyer, Christof Vulsteke iD, Se Hoon Park, Sang Joon Shin, Daniel Castellano, Giuseppe Fornarini und 13 weitere

New England Journal of Medicine · 07.03.2024 · 390 (10) · 875-888

DOI: 10.1056/nejmoa2312117 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift New England Journal of Medicine, erschienen am 07.03.2024. Verfasst von Thomas Powles und 24 weiteren Autor:innen. Beteiligte Einrichtung: From Barts Cancer Institute Biomedical Research Centre, Queen Mary University of London, London (T.P.); Hospital Universitario Virgen del Rocio, Sevi…. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Carcinoma, Transitional Cell, Antineoplastic Agents, Urologic Neoplasms. Die Arbeit wurde bisher 1184-mal zitiert (Crossref) und nennt 20 Literaturangaben. Gefördert von: Wellcome Trust, Seagen, Astellas Pharma.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, MonoclonalCarcinoma, Transitional CellAntineoplastic AgentsUrologic NeoplasmsHumansAntibodies, Monoclonal, HumanizedCisplatinUrinary Bladder NeoplasmsGemcitabineCarboplatinSurvival Analysis

Substanzen

Antibodies, MonoclonalAntibodies, Monoclonal, HumanizedCisplatinenfortumab vedotinpembrolizumabGemcitabineCarboplatinAntineoplastic Agents

Autor:innen und Institutionen

  • From Barts Cancer Institute Biomedical Research Centre, Queen Mary University of London, London (T.P.); Hospital Universitario Virgen del Rocio, Seville (B.P.V.), Hospital Universitario 12 de Octubre, Madrid (D.C.), and…

ORCID-Profile: Christof Vulsteke

Förderung

  • Wellcome Trust
  • Seagen
  • Astellas Pharma
  • Merck

Zitieren

APA

Powles, T., Valderrama, B. P., Gupta, S., Bedke, J., Kikuchi, E., Hoffman-Censits, J., Iyer, G., Vulsteke, C., Park, S. H., Shin, S. J., Castellano, D., Fornarini, G., Li, J. R., Gümüş, M., Mar, N., Loriot, Y., Fléchon, A., Duran, I., Drakaki, A., …, & EV-302 Trial Investigators (2024). Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer. New England Journal of Medicine, 390(10), 875-888. https://doi.org/10.1056/nejmoa2312117

Vancouver

Powles T, Valderrama BP, Gupta S, Bedke J, Kikuchi E, Hoffman-Censits J, et al. Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer. New England Journal of Medicine. 2024;390(10):875-888. doi:10.1056/nejmoa2312117

BibTeX
@article{Powles2024,
  author = {Powles, Thomas and Valderrama, Begoña P and Gupta, Shilpa and Bedke, Jens and Kikuchi, Eiji and Hoffman-Censits, Jean and Iyer, Gopa and Vulsteke, Christof and Park, Se Hoon and Shin, Sang Joon and Castellano, Daniel and Fornarini, Giuseppe and Li, Jian-Ri and Gümüş, Mahmut and Mar, Nataliya and Loriot, Yohann and Fléchon, Aude and Duran, Ignacio and Drakaki, Alexandra and Narayanan, Sujata and Yu, Xuesong and Gorla, Seema and Homet Moreno, Blanca and van der Heijden, Michiel S and EV-302 Trial Investigators, EV-302 Trial Investigators},
  title = {Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer},
  journal = {New England Journal of Medicine},
  year = {2024},
  volume = {390},
  number = {10},
  pages = {875--888},
  doi = {10.1056/nejmoa2312117}
}
Kostenlos starten →